Experimental nanoparticle therapy shows promise for fighting primary liver cancer

Experimental nanoparticle therapy shows promise for fighting primary liver cancer Primary liver cancer, or hepatocellular carcinoma, is the sixth most prevalent type of cancer and third-leading cause of cancer-related deaths worldwide, according to the National Cancer Institute (NCI). Incidence of … Continue reading

AbbVie gets FDA approval for Hepatitis C combination therapy

AbbVie gets FDA approval for Hepatitis C combination therapy Daklinza plus sofosbuvir resulted in 90% SVR12 in treatment-naive and 86% in treatment-experienced chronic HCV genotype 3 patients. Most people infected with HCV have no symptoms of the disease until liver … Continue reading

Bristol-Myers Hepatitis C Therapy With Sovaldi Meets Study Goals

Bristol-Myers Hepatitis C Therapy With Sovaldi Meets Study Goals Bristol has been focusing on the hepatitis C treatment—called daclatasvir—in combination with Sovaldi following the U.S. Food and Drug Administration's rejection of its new drug application in November for daclatasvir in … Continue reading